Assessment of Testicular Sertoli Cell Function in Chemotherapy – Treated Prepubertal and Pubertal Male Survivors of Childhood Cancer

M. MORALES BAZURTO; S GOTTLIEB; MG BALLERINI; MG ROPELATO; G DEL REY ; L AVERSA; M CORES; I BERGADA; RA REY; RP GRINSPON

Bahia

Congreso; Sociedad Latino-Americana de Endocrinología Pediátrica (SLEP) 21st Annual Meeting,; 2010

Sociedad Latino-Americana de Endocrinología Pediátrica (SLEP)

Background: Male germ cells are highly sensitive to chemotherapy, whereas quiescent Leydig cells seem to be less affected in prepubertal boys. Sertoli cells have rarely been studied. Objective: whereas quiescent Leydig cells seem to be less affected in prepubertal boys. Sertoli cells have rarely been studied. Objective: whereas quiescent Leydig cells seem to be less affected in prepubertal boys. Sertoli cells have rarely been studied. Objective: Male germ cells are highly sensitive to chemotherapy, whereas quiescent Leydig cells seem to be less affected in prepubertal boys. Sertoli cells have rarely been studied. Objective:Objective: To assess pituitary-testicular function, with emphasis on Sertoli cell function, in boys and adolescents with extragonadal tumors having received chemotherapy exclusively. Methods: A retrospective analysis including 51 patients treated <10yr and 38 treated between 10–18 yr. FSH and AMH levels were the primary endpoints. LH and testosterone were also assessed. Results: In 35/51 patients treated <10yr, evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. including 51 patients treated <10yr and 38 treated between 10–18 yr. FSH and AMH levels were the primary endpoints. LH and testosterone were also assessed. Results: In 35/51 patients treated <10yr, evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. including 51 patients treated <10yr and 38 treated between 10–18 yr. FSH and AMH levels were the primary endpoints. LH and testosterone were also assessed. Results: In 35/51 patients treated <10yr, evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. Methods: A retrospective analysis including 51 patients treated <10yr and 38 treated between 10–18 yr. FSH and AMH levels were the primary endpoints. LH and testosterone were also assessed. Results: In 35/51 patients treated <10yr, evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. Results: In 35/51 patients treated <10yr, evaluation before puberty (9.7ｱ2.3 yr; 3.0ｱ2.6 yr post-chemotherapy) showed normal AMH in all, with mild elevation of FSH in 31.4% and LH in 14.3%. In 30/51 cases treated <10 yr, evaluation at pubertal age (15.0ｱ2.2 yr; 8.8ｱ3.5 yr post-chemotherapy) showed low AMH in 3.8%, low testosterone in 13.3% and mildly elevated FSH and LH in 13.3%. In 38 patients treated during puberty, analysis 5.0ｱ4.5 yr post-chemotherapy showed normal AMH in all, low testosterone and moderately elevated LH in 5.2%, and elevated FSH in 28.9%. Conclusions: Like Leydig cells, Sertoli cells have low sensitivity to chemotherapy in prepubertal and pubertal males. Pubertal elevation of FSH in a subset of patients might be due to germ cell loss chemotherapy in prepubertal and pubertal males. Pubertal elevation of FSH in a subset of patients might be due to germ cell loss chemotherapy in prepubertal and pubertal males. Pubertal elevation of FSH in a subset of patients might be due to germ cell loss Like Leydig cells, Sertoli cells have low sensitivity to chemotherapy in prepubertal and pubertal males. Pubertal elevation of FSH in a subset of patients might be due to germ cell loss